NO3030563T3 - - Google Patents

Info

Publication number
NO3030563T3
NO3030563T3 NO14738751A NO14738751A NO3030563T3 NO 3030563 T3 NO3030563 T3 NO 3030563T3 NO 14738751 A NO14738751 A NO 14738751A NO 14738751 A NO14738751 A NO 14738751A NO 3030563 T3 NO3030563 T3 NO 3030563T3
Authority
NO
Norway
Application number
NO14738751A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO3030563T3 publication Critical patent/NO3030563T3/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO14738751A 2013-06-27 2014-06-26 NO3030563T3 (en:Method)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13174108 2013-06-27
PCT/EP2014/063467 WO2014207082A1 (en) 2013-06-27 2014-06-26 Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
EP14738751.8A EP3030563B1 (en) 2013-06-27 2014-06-26 Pyrrolo [3,2-d] pyrimidine derivatives for the treatment of viral infections and other diseases

Publications (1)

Publication Number Publication Date
NO3030563T3 true NO3030563T3 (en:Method) 2018-01-06

Family

ID=48692351

Family Applications (1)

Application Number Title Priority Date Filing Date
NO14738751A NO3030563T3 (en:Method) 2013-06-27 2014-06-26

Country Status (25)

Country Link
US (2) US10385054B2 (en:Method)
EP (1) EP3030563B1 (en:Method)
JP (2) JP6763769B2 (en:Method)
KR (1) KR102311234B1 (en:Method)
CN (2) CN105473592B (en:Method)
AU (2) AU2014301089B2 (en:Method)
BR (1) BR112015032546B1 (en:Method)
CA (1) CA2913028C (en:Method)
CL (1) CL2015003686A1 (en:Method)
DK (1) DK3030563T3 (en:Method)
EA (2) EA202090258A3 (en:Method)
ES (1) ES2645950T3 (en:Method)
HR (1) HRP20171720T1 (en:Method)
HU (1) HUE037125T2 (en:Method)
IL (3) IL242655B (en:Method)
MX (2) MX392130B (en:Method)
MY (1) MY176142A (en:Method)
NO (1) NO3030563T3 (en:Method)
PH (1) PH12015502780B1 (en:Method)
PL (1) PL3030563T3 (en:Method)
PT (1) PT3030563T (en:Method)
SG (2) SG10201803331PA (en:Method)
SI (1) SI3030563T1 (en:Method)
UA (1) UA117590C2 (en:Method)
WO (1) WO2014207082A1 (en:Method)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3330257T3 (pl) 2011-04-08 2020-06-15 Janssen Sciences Ireland Unlimited Company Pochodne pirymidyny do leczenia zakażeń wirusowych
NO3030563T3 (en:Method) * 2013-06-27 2018-01-06
JOP20150177B1 (ar) 2014-08-01 2021-08-17 Janssen Pharmaceutica Nv مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2
MA44334A (fr) 2015-10-29 2018-09-05 Novartis Ag Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
AU2016374571B2 (en) 2015-12-18 2021-05-06 Janssen Pharmaceutica Nv Radiolabelled mGluR2/3 PET ligands
CA3003962A1 (en) 2015-12-18 2017-06-22 Janssen Pharmaceutica Nv Radiolabelled mglur2/3 pet ligands
CN109476675B (zh) * 2016-07-01 2022-12-09 爱尔兰詹森科学公司 用于治疗病毒性感染的二氢吡喃并嘧啶衍生物
KR102450287B1 (ko) 2016-09-29 2022-09-30 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 바이러스 감염 및 추가적인 질환의 치료를 위한 피리미딘 프로드러그
TW202415645A (zh) * 2018-03-01 2024-04-16 愛爾蘭商健生科學愛爾蘭無限公司 ２，４－二胺基喹唑啉衍生物及其醫學用途
WO2019209811A1 (en) 2018-04-24 2019-10-31 Bristol-Myers Squibb Company Macrocyclic toll-like receptor 7 (tlr7) agonists
US11554120B2 (en) 2018-08-03 2023-01-17 Bristol-Myers Squibb Company 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor
JP7287708B2 (ja) 2019-02-08 2023-06-06 プロジェニア インコーポレイテッド Ｔｏｌｌ－ｌｉｋｅ受容体７または８アゴニストとコレステロールの結合体およびその用途
US20230348468A1 (en) 2020-01-27 2023-11-02 Bristol-Myers Squibb Company 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
US20230118688A1 (en) 2020-01-27 2023-04-20 Bristol-Myers Squibb Company 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
US20230041738A1 (en) 2020-01-27 2023-02-09 Bristol-Myers Squibb Company 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
EP4097101A1 (en) 2020-01-27 2022-12-07 Bristol-Myers Squibb Company 1h-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (tlr7) agonists
EP4097104A1 (en) 2020-01-27 2022-12-07 Bristol-Myers Squibb Company 1h-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (tlr7) agonists
US20230127326A1 (en) 2020-01-27 2023-04-27 Bristol-Myers Squibb Company C3-SUBSTITUTED 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
CN115643805B (zh) 2020-01-27 2024-11-08 百时美施贵宝公司 作为Toll样受体7(TLR7)激动剂的1H-吡唑并[4,3-d]嘧啶化合物
EP4097105A1 (en) 2020-01-27 2022-12-07 Bristol-Myers Squibb Company 1h-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (tlr7) agonists
CN115279765B (zh) 2020-01-27 2024-11-12 百时美施贵宝公司 作为Toll样受体7(TLR7)激动剂的1H-吡唑并[4,3-d]嘧啶化合物
US20230100429A1 (en) 2020-03-02 2023-03-30 Progeneer Inc. Live-pathogen-mimetic nanoparticles based on pathogen cell wall skeleton, and production method thereof
US20230355750A1 (en) 2020-08-04 2023-11-09 Progeneer Inc. Kinetically acting adjuvant ensemble
JP7690222B2 (ja) 2020-08-04 2025-06-10 プロジェニア インコーポレイテッド 動力学的制御が可能なアジュバントを含むｍＲＮＡワクチン
CN116056725A (zh) 2020-08-04 2023-05-02 蛋白科技先鋒 活性位点暂时灭活的功能性药物与Toll样受体7或8激动剂的缀合物及其用途

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2610889B2 (ja) 1987-09-03 1997-05-14 日本臓器製薬株式会社 新規架橋アデニン誘導体
CA2230808C (en) 1996-07-03 2006-08-15 Japan Energy Corporation A novel purine derivative
WO1998008847A1 (en) 1996-08-28 1998-03-05 Pfizer Inc. Substituted 6,5-hetero-bicyclic derivatives
US6265577B1 (en) 1996-10-04 2001-07-24 Kyorin Pharmaceuticals Co., Ltd. Pyrazolopyridylpyridazinone derivatives and process for the preparation thereof
AR012634A1 (es) 1997-05-02 2000-11-08 Sugen Inc Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
US6339089B2 (en) 1997-08-13 2002-01-15 Fujirebio Inc. Pyrimidine nucleus-containing compound and a medicament containing the same for a blood oxygen partial pressure amelioration, and a method for preparing the same
CA2311742C (en) 1997-11-28 2009-06-16 Sumitomo Pharmaceuticals Co., Ltd. 6-amino-9-benzyl-8-hydroxypurine derivatives
TW572758B (en) 1997-12-22 2004-01-21 Sumitomo Pharma Type 2 helper T cell-selective immune response inhibitors comprising purine derivatives
US6187777B1 (en) 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
CN1297447A (zh) 1998-02-17 2001-05-30 图拉列克股份有限公司 抗病毒嘧啶衍生物
US6110929A (en) 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
JP4342007B2 (ja) 1998-08-10 2009-10-14 大日本住友製薬株式会社 キナゾリン誘導体
JP4315300B2 (ja) 1998-08-10 2009-08-19 大日本住友製薬株式会社 新規なキナゾリン誘導体
WO2000012487A1 (en) 1998-08-27 2000-03-09 Sumitomo Pharmaceuticals Co., Ltd. Pyrimidine derivatives
US6583148B1 (en) 1999-04-08 2003-06-24 Krenitsky Pharmaceuticals, Inc. Neurotrophic substituted pyrimidines
CA2323008C (en) 1999-10-11 2005-07-12 Pfizer Inc. Pharmaceutically active compounds
WO2002088079A2 (en) 2001-05-01 2002-11-07 Bristol-Myers Squibb Company Dual inhibitors of pde 7 and pde 4
WO2003055890A1 (en) 2001-12-21 2003-07-10 Bayer Pharmaceuticals Corporation Thienopyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
US7091232B2 (en) 2002-05-21 2006-08-15 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
TW200407143A (en) 2002-05-21 2004-05-16 Bristol Myers Squibb Co Pyrrolotriazinone compounds and their use to treat diseases
EP1552842A1 (en) 2002-06-07 2005-07-13 Kyowa Hakko Kogyo Co., Ltd. Bicyclic pyrimidine derivatives
NZ539064A (en) 2002-09-27 2007-09-28 Dainippon Sumitomo Pharma Co Novel adenine compound and use thereof
US8455458B2 (en) 2002-10-16 2013-06-04 Arthrodynamic Technologies, Animal Health Division, Inc. Composition and method for treating connective tissue damage
BRPI0411514A (pt) 2003-06-20 2006-08-01 Coley Pharm Gmbh antagonistas de receptor toll-like de molécula pequena
GEP20084545B (en) 2003-09-05 2008-11-25 Anadys Pharmaceuticals Inc Introducing tlr7 ligands and prodrugs thereof for the treatment of hepatitis c viral infection
EP1728792A4 (en) 2004-03-26 2010-12-15 Dainippon Sumitomo Pharma Co 8-OXOADENINE COMPOUND
TWI392678B (zh) 2004-03-26 2013-04-11 Dainippon Sumitomo Pharma Co ９-取代-８-氧基腺嘌呤化合物
WO2007084413A2 (en) 2004-07-14 2007-07-26 Ptc Therapeutics, Inc. Methods for treating hepatitis c
AU2005271161B2 (en) 2004-08-10 2011-05-12 Janssen Pharmaceutica N.V. HIV inhibiting 1,2,4-triazin-6-one derivatives
AU2005304040B2 (en) 2004-11-09 2009-04-23 F. Hoffmann-La Roche Ag Aminoquinazolines compounds
US7498409B2 (en) 2005-03-24 2009-03-03 Schering Corporation Screening assay for TLR7, TLR8 and TLR9 agonists and antagonists
EP1888587A1 (en) 2005-05-04 2008-02-20 Pfizer Limited 2-amido-6-amino-8-oxopurine derivatives as toll-like receptor modulators for the treatment of cancer and viral infections, such as hepatitis c
MX2007013715A (es) * 2005-05-05 2008-01-28 Ardea Biosciences Inc Diaril-purinas, azapurinas y deazapurinas como inhibidores no nucleosidos de transcriptasa inversa para el tratamiento del virus de inmunodeficiencia humana.
AR054122A1 (es) 2005-05-12 2007-06-06 Tibotec Pharm Ltd Pirido[2,3-d]pirimidas utiles como inhibidores de hcv, y metodos para la preparacion de las mismas
US7994360B2 (en) 2005-05-16 2011-08-09 Xtl Biopharmaceuticals Ltd. Benzofuran compounds
JP4850911B2 (ja) 2005-09-01 2012-01-11 エフ．ホフマン−ラ ロシュ アーゲー Ｐ２ｘ３およびｐ２ｘ２／３モジュレーターとしてのジアミノピリミジン
WO2007034881A1 (ja) 2005-09-22 2007-03-29 Dainippon Sumitomo Pharma Co., Ltd. 新規アデニン化合物
WO2007056208A2 (en) 2005-11-02 2007-05-18 Cytovia, Inc. N-arylalkyl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof
WO2007063934A1 (ja) 2005-12-02 2007-06-07 Mitsubishi Tanabe Pharma Corporation 脂環式複素環化合物
JP2009528989A (ja) 2006-02-17 2009-08-13 ファイザー・リミテッド Ｔｌｒ７変調剤としての３−デアザプリン誘導体
US8673929B2 (en) 2006-07-20 2014-03-18 Gilead Sciences, Inc. 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections
US9259426B2 (en) 2006-07-20 2016-02-16 Gilead Sciences, Inc. 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections
ES2571028T3 (es) 2006-12-07 2016-05-23 Genentech Inc Compuestos inhibidores de fosfoinositida 3-cinasa y métodos de uso
AU2007335962B2 (en) 2006-12-20 2012-09-06 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Antiviral indoles
ES2456964T3 (es) 2007-02-07 2014-04-24 The Regents Of The University Of California Conjugados de agonistas de TLR sintéticos y usos de los mismos
JP2008222557A (ja) * 2007-03-08 2008-09-25 Kotobuki Seiyaku Kk ピロロ［３，２−ｄ］ピリミジン誘導体及びこれを有効成分とする医薬組成物
EP2132209B8 (en) 2007-03-19 2014-04-16 AstraZeneca AB 9-substituted-8-oxo-adenine compounds as toll-like receptor (tlr7 ) modulators
PE20081887A1 (es) 2007-03-20 2009-01-16 Dainippon Sumitomo Pharma Co Nuevo compuesto de adenina
WO2008114819A1 (ja) 2007-03-20 2008-09-25 Dainippon Sumitomo Pharma Co., Ltd. 新規アデニン化合物
US9150556B2 (en) 2007-05-22 2015-10-06 Boehringer Ingelheim International Gmbh Benzimidazolone chymase inhibitors
EA021463B1 (ru) 2007-06-29 2015-06-30 Джилид Сайэнс, Инк. Пуриновые производные и их применение в качестве модуляторов толл-подобного рецептора 7
EA201000201A1 (ru) 2007-08-10 2010-12-30 ГЛАКСОСМИТКЛАЙН ЭлЭлСи Азотсодержащие бициклические химические вещества для лечения вирусных инфекций
US8440681B2 (en) 2007-08-28 2013-05-14 Irm Llc 2-biphenylamino-4-aminopyrimidine derivatives as kinase inhibitors
WO2009030998A1 (en) 2007-09-05 2009-03-12 Coley Pharmaceutical Group, Inc. Pyrimidine compounds as toll-like receptor (tlr) agonists
PE20091236A1 (es) * 2007-11-22 2009-09-16 Astrazeneca Ab Derivados de pirimidina como immunomoduladores de tlr7
BRPI0821836A2 (pt) 2007-12-24 2015-06-16 Tibotec Pharm Ltd Indóis macrocíclicos como inibidores do vírus da hepatite c
EP2259788A4 (en) 2008-02-07 2011-03-16 Univ California TREATMENT OF BLADDER DISEASES WITH A TLR7 ACTIVATOR
JP2011518882A (ja) 2008-04-28 2011-06-30 メルク・シャープ・エンド・ドーム・コーポレイション Ｈｃｖｎｓ３プロテアーゼ阻害剤
US9081591B2 (en) 2008-06-27 2015-07-14 Kyocera Corporation User interface generation apparatus
US8946239B2 (en) 2008-07-10 2015-02-03 Duquesne University Of The Holy Spirit Substituted pyrrolo, -furano, and cyclopentylpyrimidines having antimitotic and/or antitumor activity and methods of use thereof
UY31982A (es) 2008-07-16 2010-02-26 Boehringer Ingelheim Int Derivados de 1,2-dihidropiridin-3-carboxamidas n-sustituidas
BRPI1010937A2 (pt) 2009-05-21 2019-09-24 Astrazeneca Ab composto, uso de um composto, e, método para tratar câncer
US8637525B2 (en) 2009-07-31 2014-01-28 Bristol-Myers Squibb Company Compounds for the reduction of beta-amyloid production
TWI468402B (zh) 2009-07-31 2015-01-11 必治妥美雅史谷比公司 降低β－類澱粉生成之化合物
WO2011049988A2 (en) 2009-10-20 2011-04-28 Eiger Biopharmaceuticals, Inc. Indazoles to treat flaviviridae virus infection
AU2010310813B2 (en) 2009-10-22 2015-06-18 Gilead Sciences, Inc. Derivatives of purine or deazapurine useful for the treatment of (inter alia) viral infections
KR101094446B1 (ko) 2009-11-19 2011-12-15 한국과학기술연구원 단백질 키나아제 저해활성을 가지는 2,4,7-치환된 티에노［3,2-ｄ］피리미딘 화합물
JP2013032290A (ja) 2009-11-20 2013-02-14 Dainippon Sumitomo Pharma Co Ltd 新規縮合ピリミジン誘導体
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
WO2012066335A1 (en) 2010-11-19 2012-05-24 Astrazeneca Ab Phenol compounds als toll -like receptor 7 agonists
WO2012067269A1 (en) 2010-11-19 2012-05-24 Dainippon Sumitomo Pharma Co., Ltd. Aminoalkoxyphenyl compounds and their use in the treatment of disease
PL3330257T3 (pl) 2011-04-08 2020-06-15 Janssen Sciences Ireland Unlimited Company Pochodne pirymidyny do leczenia zakażeń wirusowych
MX347966B (es) 2011-05-18 2017-05-18 Janssen Sciences Ireland Uc Derivados de quinazolina para el tratamiento de infecciones viricas y otras enfermedades.
MX347596B (es) 2011-11-09 2017-05-03 Janssen Sciences Ireland Uc Derivados de purina para el tratamiento de infecciones viricas.
NZ627036A (en) 2012-02-08 2016-03-31 Janssen Sciences Ireland Uc Piperidino-pyrimidine derivatives for the treatment of viral infections
HUE054031T2 (hu) 2012-04-24 2021-08-30 Vertex Pharma DNS-PK inhibitorok
JP6250046B2 (ja) 2012-07-13 2017-12-20 ヤンセン・サイエンシズ・アイルランド・ユーシー ウイルス感染症の処置のための大環状プリン
IN2015MN00478A (en:Method) 2012-08-10 2015-09-04 Janssen Sciences Ireland Uc
EP2712866A1 (en) 2012-10-01 2014-04-02 Centre National de la Recherche Scientifique (CNRS) 1,2,4-triazine derivatives for the treatment of viral infections
CN111606861A (zh) 2012-10-05 2020-09-01 爱尔兰詹森科学公司 用于治疗病毒感染和另外的疾病的酰氨基嘧啶衍生物
HUE037064T2 (hu) 2012-10-10 2018-08-28 Janssen Sciences Ireland Uc Pirrolo[3,2-d]-pirimidin származékok vírusos fertõzések és egyéb betegségek kezelésére
US9663474B2 (en) 2012-11-16 2017-05-30 Janssen Sciences Ireland Uc Heterocyclic substituted 2-amino quinazoline derivatives for the treatment of viral infections
CN105189468B (zh) 2013-02-21 2018-10-30 爱尔兰詹森科学公司 用于治疗病毒性感染的2-氨基嘧啶衍生物
KR102280554B1 (ko) 2013-03-29 2021-07-22 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 바이러스 감염증의 치료를 위한 거대환식 데아자-퓨리논
NO3030563T3 (en:Method) * 2013-06-27 2018-01-06
WO2015014815A1 (en) 2013-07-30 2015-02-05 Janssen R&D Ireland THIENO[3,2-d]PYRIMIDINES DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS
US9701661B2 (en) 2014-07-11 2017-07-11 Northwestern University 2-imidazolyl-pyrimidine scaffolds as potent and selective inhibitors of neuronal nitric oxide synthase

Also Published As

Publication number Publication date
HRP20171720T1 (hr) 2017-12-29
EA034893B1 (ru) 2020-04-02
CA2913028C (en) 2022-03-08
NZ754320A (en) 2021-07-30
SG11201510637UA (en) 2016-01-28
IL264402A (en) 2019-02-28
EA202090258A3 (ru) 2020-07-31
PT3030563T (pt) 2017-11-15
CN105473592A (zh) 2016-04-06
CN109369643A (zh) 2019-02-22
MX2015017671A (es) 2016-03-03
US10385054B2 (en) 2019-08-20
AU2014301089B2 (en) 2018-10-04
HUE037125T2 (hu) 2018-08-28
PH12015502780A1 (en) 2016-03-21
BR112015032546B1 (pt) 2022-05-17
EP3030563B1 (en) 2017-08-09
EA201690093A1 (ru) 2016-04-29
AU2014301089A1 (en) 2015-12-03
MX361527B (es) 2018-12-07
SI3030563T1 (sl) 2017-12-29
DK3030563T3 (da) 2017-11-20
SG10201803331PA (en) 2018-06-28
MX392130B (es) 2025-03-21
CL2015003686A1 (es) 2016-08-19
US20200002342A1 (en) 2020-01-02
AU2018274911B2 (en) 2020-05-14
KR20160026880A (ko) 2016-03-09
ES2645950T3 (es) 2017-12-11
PL3030563T3 (pl) 2018-01-31
AU2018274911A1 (en) 2019-01-03
JP2016526550A (ja) 2016-09-05
EA202090258A2 (ru) 2020-05-31
US10781216B2 (en) 2020-09-22
BR112015032546A2 (pt) 2017-07-25
WO2014207082A1 (en) 2014-12-31
CN105473592B (zh) 2018-10-26
PH12015502780B1 (en) 2016-03-21
IL242655B (en) 2018-04-30
EP3030563A1 (en) 2016-06-15
UA117590C2 (uk) 2018-08-27
CN109369643B (zh) 2021-05-18
US20160168150A1 (en) 2016-06-16
IL264402B (en) 2019-09-26
IL258253B (en) 2019-02-28
HK1218116A1 (zh) 2017-02-03
IL258253A (en) 2018-05-31
MY176142A (en) 2020-07-24
JP6763769B2 (ja) 2020-09-30
JP2020203929A (ja) 2020-12-24
KR102311234B1 (ko) 2021-10-12
CA2913028A1 (en) 2014-12-31
NZ714267A (en) 2021-06-25

Similar Documents

Publication Publication Date Title
BR112015007533A2 (en:Method)
BR112016000850A2 (en:Method)
BR112016011272A2 (en:Method)
BR112014018502A2 (en:Method)
BR112014019326A2 (en:Method)
BR112016004142A2 (en:Method)
BR112014018516A2 (en:Method)
BR112014018480A2 (en:Method)
BR112014020341A2 (en:Method)
BR112014017855A2 (en:Method)
BR112016001139A2 (en:Method)
NO3030563T3 (en:Method)
BR112014021878A2 (en:Method)
BR112016011749A2 (en:Method)
BR112016008659A2 (en:Method)
BR112014018468A2 (en:Method)
BR112014017901A2 (en:Method)
BR112016012364A2 (en:Method)
BR112014019204A2 (en:Method)
BR112014018207A2 (en:Method)
BR112015015948A2 (en:Method)
BR112016012591A2 (en:Method)
BR112014018578A2 (en:Method)
BR112014018483A2 (en:Method)
BR112015015312A2 (en:Method)